Baiyun Mountain: The subsidiary's Zhaoyanming tablet has received approval for clinical trials of a newly added functional indication.

Baiyun Mountain announced that recently, its subsidiary Zhongyi Pharmaceutical received the "Approval Notice for Clinical Drug Trials" from the National Medical Products Administration, granting approval to conduct clinical trials for the new therapeutic functions of Zhangyanming tablets for dry eye. As of the date of the announcement, Zhongyi Pharmaceutical has invested approximately 10.1114 million yuan in research related to the treatment of dry eye with Zhangyanming tablets. In 2025, the sales revenue of Zhongyi Pharmaceutical's Zhangyanming tablets is projected to be 14.51 million yuan. The drug development cycle is long, with many steps involved, and there are uncertainties; the company will disclose progress in a timely manner.